Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma, Kaposi × talimogene laherparepvec × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 10 Sarcoma 4 Carcinoma, Merkel Cell 2 Skin Neoplasms 1 Sezary Syndrome 1 Sarcoma, Kaposi 1 Paget Disease, Extramammary 1 Neoplasm Metastasis 1 Mycosis Fungoides 1 Muir-Torre Syndrome 1 Microcystic adnexal carcinoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Liposarcoma 1 Leiomyosarcoma 1 Inflammatory Breast Neoplasms 1 Histiocytoma, Malignant Fibrous 1 Eccrine Porocarcinoma 1 Carcinoma, Signet Ring Cell 1 Carcinoma, Basosquamous 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1 Adenocarcinoma, Papillary 1

Interventions

Paclitaxel 3 Nelfinavir 3 Bevacizumab 3 pembrolizumab 2 Zidovudine 2 Valganciclovir 2 Semaxinib 2 Ritonavir 2 Propranolol 2 Interferon alpha-2 2 Indinavir 2 Filgrastim 2 Etoposide 2 Doxorubicin 2 vesnarinone 1 tocilizumab 1 tin etiopurpurin 1 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 talimogene laherparepvec 1 nirogacestat 1 liposomal doxorubicin 1 lenvatinib 1 ixazomib 1 halofuginone 1 etoposide phosphate 1 Vincristine 1 Sunitinib 1 Saquinavir 1 Ro 24-7429 1 Rituximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065152 2022-06-10

KAPVEC

Assistance Publique - Hôpitaux de Paris

Phase 2 Unknown

Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon ⚡